Portal de investigación
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+acute myeloid leukemia treated with intensive chemotherapy
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bertoli, Sarah
- Landberg, Niklas
- Berard, Emilie
- Gondran, Camille
- Largeaud, Laetitia
- De Mas, Veronique
- Dumas, Pierre-Yves
- Pigneux, Arnaud
- Bidet, Audrey
- Garciaz, Sylvain
- Gabellier, Ludovic
- Roth-Guepin, Gabrielle
- Orvain, Corentin
- Peterlin, Pierre
- Birsen, Rudy
- Alexis, Magda
- Carre, Martin
- Tavernier, Emmanuelle
- Simonet, Marion Boissard
- Himberlin, Chantal
- Maynadie, Marc
- Laribi, Kamel
- Molucon-Chabrot, Cecile
- Belhabri, Amine
- Chraibi, Samy
- Cabrera, Quentin
- Lebon, Delphine
- Raffoux, Emmanuel
- Cluzeau, Thomas
- Micol, Jean-Baptiste
- Leclerc, Mathieu
- Berthon, Celine
- Dombret, Herve
- Juliusson, Gunnar
- Robelius, Anna
- Lehmann, Soren
- Jadersten, Martin
- Wennstrom, Lovisa
- Botella, Carmen
- Burgues, Juan Miguel Bergua
- Garcia, Raimundo
- Amigo, Mariluz
- Ramirez, Patricia Garcia
- Sossa, Claudia
- Alonso-Dominguez, Juan Manuel
- Dohner, Hartmut
- Dohner, Konstanze
- Spath, Daniela
- Kuhn, Michael
- Lengerke, Claudia
- Tischler, Hans-Jorg
- Rollig, Christoph
- Ruhnke, Leo
- Thiede, Christian
- Burchert, Andreas
- Serve, Hubert
- Mueller-Tidow, Carsten
- Baldus, Claudia
- Versluis, Jurjen
- Valk, Peter
- Kristensen, Daniel
- Roug, Anne Stidsholt
- Mayer, Jiri
- Kontro, Mika
- Ettala, Pia
- Lazarevic, Vladimir
- Recher, Christian
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 991-993
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Bertoli,S,Landberg,N,Berard,E,Gondran,C,Largeaud,L,De Mas,V,Dumas,P et al. The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+acute myeloid leukemia treated with intensive chemotherapy. 67th Annual Meeting of the American-Society-of-Hematology (ASH). 2025. Orlando. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2025 p.p. 991-993.